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Background: Eph receptors and ephrin ligands have several functions including angiogenesis, cell migration, axon 
guidance, fluid homeostasis, oncogenesis, inflammation and injury repair. The EphA2 receptor  potentially  mediates the 
regulation of vascular permeability and inflammation in response to lung injury.
Methods: Mice were divided into 3 experimental groups to study the role of EphA2 signaling in the lipopolysaccharide 
(LPS) -induced lung injury model i.e., IgG+phosphate-buffered saline (PBS) group (IgG instillation before PBS exposure), 
IgG+LPS group (IgG instillation before LPS exposure) and EphA2 monoclonal antibody (mAb)+LPS group (EphA2 mAb 
pretreatment before LPS exposure).
Results: EphA2 and ephrinA1 were upregulated in LPS-induced lung injury. The lung injury score of the EphA2 
mAb+LPS group was lower than that of the IgG+LPS group (4.30±2.93 vs. 11.45±1.20, respectively; p=0.004). Cell counts 
(EphA2 mAb+LPS: 11.33×104±8.84×104 vs. IgG+LPS: 208.0×104±122.6×104; p=0.018) and total protein concentrations 
(EphA2 mAb+LPS: 0.52±0.41 mg/mL vs. IgG+LPS: 1.38±1.08 mg/mL; p=0.192) were decreased in EphA2 mAb+LPS 
group, as compared to the IgG+LPS group. In addition, EphA2 antagonism reduced the expression of phospho-p85, 
phosphoinositide 3-kinase 110γ, phospho-Akt, nuclear factor κB, and proinflammatory cytokines.
Conclusion: This results of the study indicated a role for EphA2-ephrinA1 signaling in the pathogenesis of LPS-induced 
lung injury. Furthermore, EphA2 antagonism inhibits the phosphoinositide 3-kinase–Akt pathway and attenuates 
inflammation.
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Introduction
The Eph tyrosine kinase receptor and ephrin ligand are cell 
surface-bound and are involved in cell-to-cell communica-
tion1,2. The influence of Eph ephrin activation differs depend-
ing on the cell type and environment. Eph- ephrin signaling 
contributes to several functions including vasculogenesis, 
angiogenesis, cell migration, axon guidance, fluid homeostasis 
and repair after injury1-3. A great deal of recent research has fo-
cused on the complex role of Eph and ephrin in malignancy4,5. 
According to several studies, Eph receptors and ephrin ligands 
affect multiple oncogenic signaling pathways such as MAPK/
ERK, phosphoinositide 3-kinase (PI3K), E-cadherin and integ-
rin/FAK/paxillin4,6-8. In addition to bidirectional signaling, Eph 
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receptors and ephrin ligands function independently of each 
other or in conjunction with other cell surface communica-
tion systems1.
Eph-Ephrin proteins may play a role in inflammation 
through phenotypic changes in the vascular endothelium, 
which allow movement of inflammatory cells into the injured 
tissue3. There are studies on the role of EphA2-ephrinA1 sig-
naling in lung injury9-11. These studies have shown that both 
EphA2 and ephrinA1 increase in bleomycin-induced lung 
injury and lung injury due to viral infection and hypoxia9,10, 
contrary to counter-directed changes in expressional regula-
tion of Eph and ephrin during lipopolysaccharide (LPS) fever 
in rats11. In the bleomycin-induced lung injury model, EphA2 
knockout mice showed reduced permeability and less inflam-
matory response than wild type mice9. Similarly, in lung injury 
due to viral infection and hypoxia, EphA2 antagonism with 
EphA2/Fc and anti-EphA2 antibody reduced vascular leakage 
and albumin extravasation10.
In this study, we investigated the expression of Eph-ephrin 
proteins and the effect of EphA2 monoclonal antibody (mAb) 
pretreatment in an LPS induced lung injury model. Also, we 
studied the association between EphA2 signaling and other 
known signal pathways of LPS-induced lung injury.
Materials and Methods
1. Experimental animals
Experiments were conducted in accordance with proto-
cols approved by the institutional animal care committee 
of the Medical College of Yonsei University. Wild type male 
C57BL/6J mice, 8–10 weeks of age and weighing 20–24 g were 
purchased from Orient Bio (Seongnam, Korea). All animals 
were supplied with food and water and were subjected to a 
similar day and night light cycle.
2. Study design
Animals were studied in three experimental groups: the 
IgG+phosphate-buffered saline (PBS) group, the IgG+LPS 
group and the EphA2 mAb+LPS group. The EphA2 mAb+LPS 
group was divided into two subgroups according to the dose 
of EphA2 mAb (2 μg and 4 μg). Under inhalation anesthesia 
using isoflurane, the mice inhaled 4 μg of mouse IgG (Cat# 
ab37355; Abcam, Cambridege, MA, USA) or monoclonal rat 
EphA2 antibody (Cat# MAB639; R&D Systems, Minneapolis, 
MN, USA) in 50 μL PBS 1 hour prior to instillation experi-
ments10. After pretreatment, mice underwent intranasal instil-
lation of 50 μL PBS or Escherichia coli  LPS (E.coli 0127: B8; 
Sigma, St. Louis, MO, USA) 40 μg/g in 50 μL PBS. The intrana-
sal administration was performed by gradually releasing the 
solution into the nostril with the help of microsyringe (Cat# 
7637-01; Hamilton Company, Reno, NV, USA)12. The rate of 
release was adjusted to allow the mouse to inhale the solution 
completely without trying to form bubbles.
All mice were sacrificed 48 hours after treatment and lung 
tissue was harvested for analysis. For bronchoalveolar lavage 
fluid (BALF) studies, lungs were lavaged via the trachea with 
two 1-mL aliquots of saline. After the BALF was centrifuged, 
the cell pellets were used for differential cell counts and the 
supernatants were used for quantitative analysis of protein by 
the Bradford protein assay. While left lung tissue was used for 
histological studies, right lung tissue was prepared for Western 
blotting and quantitative cytokine enzyme-linked immuno-
sorbent assay (ELISA).
3. Histopathology
Left lungs were inflated and fixed with 4% paraformalde-
hyde before being embedded in paraffin and sectioned. Semi-
quantitative grading of lung injury on hematoxylin and eosin–
stained sections was performed as previously described13.
4. Western blotting and cytokine ELISA
The right lung homogenate lysates were centrifuged at 
13,000 ×g for 30 minutes at 4oC. Equal amounts of protein 
were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose membrane 
before immunoblotting with primary antibodies, as indicated. 
Membranes were incubated with anti-rabbit or anti-mouse 
IgG horseradish peroxidase conjugated antibodies and de-
veloped using a Super-Signal West Pico chemiluminescence 
detection kit (Pierce, Rockford, IL, USA). The band images 
were quantified using the Alpha Ease FC software version 4.1.0 
(Alpha Innotech, San Leandro, CA, USA).
The antibodies used in this study included rabbit EphA2 
(1:1,000, Thermo Fisher Scientific, Bremen, Germany), goat 
ephrinA1 (1:1,000, Thermo Fisher Scientific), rabbit phos-
phate–Akt (1:1,000, Cell Signaling Technologies, Beverly, MA, 
USA), rabbit Akt (1:1,000, Cell Signaling Technologies), rabbit 
phosphate-p85 (1:500, Cell Signaling Technologies), rabbit 
p85 (1:1,000, Cell Signaling Technologies), rabbit PI3 kinase 
110γ (1:1,000, Cell Signaling Technologies), rabbit α-tubulin 
(1:1,000, Cell Signaling Technologies), rabbit phosphate–p65 
nuclear factor κB (NF-κB; 1:500, Thermo Fisher Scientific), 
rabbit p65 NF-κB (1:500, Thermo Fisher Scientific), mouse 
phosphate-IκBα (1:500, Cell Signaling Technologies) and 
mouse IκBα (1:500, Cell Signaling Technologies). Measure-
ment of keratinocyte chemoattractant (KC/CXCL1), macro-
phage inflammatory protein 2 (MIP-2), interleukin (IL)-1β, IL-
6, and tumor necrosis factor α (TNF-α) were performed on 
whole-lung homogenates using quantified ELISA kits (MIL-
LIPLEX MAG Mouse Cytokine/Chemokine kit from Millipore, 
Billerica, MA, USA).
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5. Statistical analysis 
Statistical analysis was performed using Prism version 5.0 
(Graphpad Software, Durham, NC, USA). Two group com-
parisons were performed with an unpaired student t test. Data 
are expressed as mean±SD for each group. Differences were 
considered significant at p<0.05.
Results
1. EphA2 and ephrinA1 are upregulated in LPS induced 
lung injury
As shown in Figure 1, Western blotting studies demonstrat-
ed a significant increase in EphA2 and ephrinA1 protein ex-
pression after LPS challenge. Both EphA2 and ephrinA1 pro-
tein expression were reduced when EphA2 mAb was instilled 
as pretreatment. Also, the degree of decline was higher in the 
4 μg EphA2 mAb subgroup than the 2 μg mAb subgroup in 
both EphA2 and ephrinA1 (Figure 1).
2. EphA2 antagonism attenuates LPS induced lung injury
In the IgG+PBS group, neutrophil recruitment, alveolar wall 
thickening and hemorrhage were not observed, contrary to 
the results of the IgG+LPS group (Figure 2A), where hyaline 
membrane formation, neutrophils in the alveolar and intersti-
tium space and thickening of alveolar septa were remarkably 
increased (Figure 2B). The EphA2 mAb+LPS groups demon-
strated reduced neutrophil infiltration and alveolar thickening 
compared with the IgG+LPS group (Figure 2C, D). 
Figure 3 shows the lung injury scores, bronchoalveolar la-
vage cell counts and protein concentrations of the four groups. 
The lung injury score of the EphA2 mAb 4 μg+LPS group was 
lower than that of the IgG+LPS group (4.30±2.93 vs.11.45±1.20, 
respectively; p=0.004). LPS caused a significant increase in cell 
counts and concentration of total protein in the lung lavage 
fluid. LPS-induced lung injury was attenuated by pretreat-
ment with EphA2 mAb. Cell counts were significantly less 
(EphA2 mAb 4 μg+LPS: 11.33×104±8.84×104 vs. IgG+LPS: 
208.0×104±122.6×104; p=0.018) and concentrations of total 
protein were lower (EphA2 mAb 4 μg+LPS: 0.52±0.41 mg/mL 
vs. IgG+LPS: 1.38±1.08 mg/mL; p=0.192) in EphA2 mAb+LPS 
group, compared with IgG+LPS group. 
3. EphA2 regulates expression of the PI3K-Akt pathway
To elucidate whether the LPS-induced injury related signal 
pathway is regulated by EphA2-ephrinA1 signaling, the PI3K-
Figure 1. The expression of EphA2 and 
ephrinA1 in lung lysates after lipopoly-
saccharide (LPS) exposure, as shown 
by Western blots (A) and densitometry 
(B, C). IgG pretreatment increased the 
expression of EphA2 and ephrinA1 after 
LPS exposure; whereas, EphA2 mono-
clonal antibody pretreatment reduced 
the expression of EphA2 and ephrinA1 
after LPS exposure. Values are presented 
as mean±SD. PBS: phosphate buffered 
saline.
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Akt pathway was assessed by Western blot analysis in the 
IgG+PBS, IgG+LPS, and EphA2 mAb+LPS groups (Figures 4, 
5B).
Compared to the IgG+PBS group, the IgG+LPS group 
showed significantly increased phospho-p85 and PI3K 110γ 
and phospho-Akt. After EphA2 mAb pretreatment, the expres-
sion of PI3K 110γ and phospho-Akt by LPS challenge were 
reduced, which indicated the inhibitory effect of EphA2 mAb 
(PI3K 110γ, p=0.06; p-Akt, p=0.002). The regulatory subunit 
PI3K phospho-p85 was not influenced by EphA2 mAb pre-
treatment.
4. EphA2 antagonism decreased NF-κB expression and 
cytokine production
To determine whether EphA2 mAb has a protective func-
tion in inflammatory response, we assessed the expression 
of p65 NF-κB, IκB protein and cytokine levels (IL-1β, IL-6, 
KC, MIP-2, and TNF-α) by Western blot analysis and ELISA. 
EphA2 antagonism led to a decrease of p65 NF-κB and cyto-
kine production in the EphA2 mAb+LPS group compared to 
the IgG+LPS group (Figures 5B, 5C, 6).
5. EphA2-ephrinA1 signaling in LPS-induced lung injury 
EphrinA1-dependent EphA2 activation may be an unrec-
Figure 2. The effect of EphA2 monoclonal antibody pretreatment in lipopolysaccharide (LPS)-induced lung injury. Mice were intranasally 
treated with IgG or EphA2 antibody. One hour later, they were intranasally treated with phosphate buffered saline (PBS) or 40 μg LPS in PBS. 
The lungs were removed after 24 hr and stained with hematoxylin and eosin (H&E). (A) IgG+PBS group, (B) IgG+LPS group, (C) EphA2 Ab 2 
μg+LPS group, and (D) EphA2 Ab 4 μg+LPS group, n=4 per group. The IgG+LPS group (B) showed obvious neutrophil infiltration and alveo-
lar septal infiltration; however, the EphA2 Ab+LPS groups (C, D) showed attenuated lung injury (H&E stain, ×400).
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Figure 3. The effect of EphA2 monoclonal antibody pretreatment on semiquantitative lung injury scores (A), total bronchoalveolar fluid 
(BALF) cell count (B) and BALF protein concentration (C). In the lipopolysaccharide (LPS)-induced lung injury model, EphA2 antagonism 
with EphA2 monoclonal antibody led to improved lung injury scores, decreased BALF cell counts and decreased BALF proteins (p<0.05, ex-
cept BALF protein), as compared to IgG pretreatment. Values are presented as mean±SD (n=4 per group).
Fi g u re  4 .  Th e  e x p re ssi o n  o f  p h o s -
phoinositide 3-kinase (PI3K) protein 
(pp85 and 110γ) in lung lysates after lipo-
polysaccharide (LPS) exposure, as shown 
by Western blots (A) and densitometry 
(B, C). Phosphorylated 110γ (catalytic 
subunit of PI3K) levels were increased in 
mice with LPS exposure (IgG+LPS), as 
compared with controls (IgG+phosphate 
buffered saline [PBS]). Activation of 
P110γ was reduced in response to EphA2 
monoclonal antibody pretreatment 
(EphA2+LPS) (C). However, the expres-
sion of p85 (regulatory subunit of PI3K) 
protein was not consistently influenced 
by EphA2 monoclonal antibody (B). Val-
ues are presented as mean±SD.
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ognized contributor to LPS-induced lung injury. Antagoniz-
ing EphA2 not only resulted in diminished expression of the 
PI3Kγ isoform, but it also led to decreased NF-κB activation 
and expression of proinflammatory cytokines through the 
PI3K-Akt pathway. Crosstalk of EphA2 signaling with the PI3K-
Akt pathway may contribute to the neutrophil-driven inflam-
matory process in LPS-induced lung injury (Figure 7).
Discussion
Although acute lung injury accounts for significant morbid-
ity and mortality in critically ill patients, there are no specific 
effective therapies14. Thus, it is important to find a therapeutic 
target and verify the effectiveness of related treatment in acute 
lung injury.
This study demonstrates that the expression of the EphA2 
receptor and ephrinA1 ligand is upregulated in an LPS-in-
duced lung injury model. Blockage of EphA2 activation leads 
to reduction of protein leakage, recruitment of inflammatory 
cells and cytokine production. Furthermore, the EphA2 recep-
tor is involved in the PI3K/Akt signal pathway in LPS-induced 
NF-κB activation.
Eph receptors and ephrin ligands represent the largest 
family of receptor tyrosine kinases that regulate important 
processes during embryonic neuronal development, angio-
genesis and oncogenesis1,2. Emerging evidence suggests that 
Eph/ephrin plays a key role in inflammation3 and previous 
studies have established the role of EphA2 in postnatal lung 
injury9-11,15. 
Contrary to our results that both EphA2 and ephrinA1 
increased after LPS exposure, Ivanov et al.11 demonstrated 
Figure 5. The expression of Akt, p65 nuclear factor κB (NF-κB), and IκB in lung lysates after lipopolysaccharide (LPS) exposure, as shown 
by representative Western blots (A) and densitometry (B–D). The amount of phosphorylated Akt was increased in mice with LPS exposure 
(IgG+LPS), as compared with controls (IgG+PBS). LPS-induced activation of Akt was reduced in response to EphA2 monoclonal antibody 
pretreatment (EphA2+LPS) (B). The expression of phosphorylated NF-κB protein was similar to that of Akt (C). The expression of phosphor-
ylated IκB after LPS exposure was increased in mice with EphA2 monoclonal antibody pretreatment (D). Values are presented as mean±SD. 
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opposing changes in expressional regulation of the EphA2 
receptor and ephrin ligand in lung tissue in phase 2 (90 min-
ute post-LPS) of LPS exposure. The difference between the 
two studies may be due to the experiment time interval. The 
sacrifice time was 90 minutes after LPS exposure in the study 
of Ivanov et al.11, whereas it was 48 hours after LPS exposure in 
our study.
Our results are consistent with previous studies on lung 
injury after instillation of bleomycin and exposure to hypoxia 
after viral infection9,10. Both studies showed increased expres-
sion of EphA2 and ephrinA1 in lung injury and found that 
EphA2 receptor antagonism (via a EphA2 KO mouse model 
or EphA2 mAb pretreatment) provided protection against 
lung injury showing reduced permeability and protein ex-
travasation.
EphA2 contributes not just to actin cytoskeleton disruption 
leading to vascular permeability, but also to inflammation in 
lung injury. Several data suggest that actin cytoskeleton rear-
rangement may be a key preceding event during the regula-
tion of inflammatory responses16-18. Our results have revealed 
that EphA2 mAb pretreatment ameliorates lung injury by at-
tenuating the expression of cytokines and neutrophil infiltra-
tion. This is similar to bleomycin-induced lung injury, where 
the proinflammatory transcriptional factors NF-κB, CXCL1, 
Figure 6. The expression of cytokines (interleukin [IL]-1β, IL-6, KC, macrophage inflammatory protein 2 [MIP-2], and tumor necrosis factor α 
[TNF-α]) in response to EphA2 monoclonal antibody pretreatment in a lipopolysaccharide (LPS) induced lung injury model. Enzyme linked 
immunosorbent assay measurement showed differential expression of cytokines (IL-1β, IL-6, KC, MIP-2, and TNF-α) in lung tissue lysates. 
Cytokine levels were reduced in response to LPS exposure in mice with EphA2 monoclonal antibody pretreatment, as compared to those 
with IgG pretreatment (n=3 per group). Values are presented as mean±SD. 
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and CCL2 are triggered by EphA2 stimulation via the ephrin 
ligand in wild mice, but inhibited in EphA2 deficient mice9.
Although the main effect of Eph receptor-ephrin ligand sig-
naling is increased vascular permeability and inflammatory 
cell migration, the detailed mechanism in lung inflammation 
remains unclear. 
PI3K and Akt occupy an important role in modulation of 
NF-κB activation and proinflammatory cytokine production 
in numerous cell populations including neutrophils, epithe-
lial cells and fibroblasts19-22. Yum et al.23 showed that, after 
exposure to LPS, Akt is activated via PI3Kγ and this leads to 
enhanced nuclear translocation of NF-κB and reduced lung 
neutrophil apoptosis. The present study demonstrated that 
antagonizing EphA2 expression with EphA2 mAb blocked the 
PI3K–Akt–NF-κB pathway. Another study supported a direct 
correlation between EphA2 signaling and the PI3K-Akt path-
way. Holen et al.24 reported that reverse signaling through the 
ephrin A4 ligand by interaction with the EphA2 receptor led 
to Src kinase phosphorylation, PI3K-Akt activation and inhibi-
tion of cell death by apoptosis.
In view of this, the EphA2 receptor may be an important 
mediator for crosstalk between the inflammatory signal path-
way and the cell-to-cell integrity pathway. Considering that 
the expression of ephrinA1 is induced by some cytokines25,26, 
ligand-mediated activation of the EphA2 receptor is expected 
to be accelerated in lung injury. Recent research reported 
that EphA2 expression induced by tobacco smoke exposure 
in bronchial airway epithelial cells was dependent on MAPK 
(ERK, p38, and JNK) signaling15. Determining whether EphA2 
signaling communicates with these additional mechanisms in 
LPS-induced lung inflammation will require further investiga-
tion.
Since EphA2-ephrinA1 signaling was reported to regulate 
multiple oncogenesis events27, clinical trials of drugs inhibiting 
the EphA2 receptor have been ongoing in cancer patients28,29. 
Similarly, the possible role of EphA2 as a therapeutic target in 
this LPS-induced lung injury model should be verified in hu-
man studies.
In conclusion, we demonstrate that EphA2 signaling regu-
lates permeability and inflammation in LPS-induced lung 
injury and leads to activation of the PI3K–Akt–NF-κB path-
way. Moreover, the inhibition of EphA2 expression by EphA2 
mAb instillation reduces neutrophil infiltration, proinflamma-
tory cytokine production and alveolar edema. Therefore, the 
EphA2 receptor may present a potential therapeutic target in 
acute lung injury.
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